194 related articles for article (PubMed ID: 15731177)
1. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM; Kaminski MS; Leonard JP; Vose JM; Zelenetz AD; Knox SJ; Horning S; Press OW; Radford JA; Kroll SM; Capizzi RL
Blood; 2005 Jun; 105(12):4576-82. PubMed ID: 15731177
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
Roboz GJ; Bennett JM; Coleman M; Ritchie EK; Furman RR; Rossi A; Jhaveri K; Feldman EJ; Leonard JP
Leuk Res; 2007 Aug; 31(8):1141-4. PubMed ID: 17475326
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
Ong DM; Farrugia H; Wei A
Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
Elstrom RL; Ruan J; Christos PJ; Martin P; Lebovic D; Osborne J; Goldsmith S; Greenberg J; Furman RR; Avram A; Putman R; Chapman E; Mazumdar M; Griffith K; Coleman M; Leonard JP; Kaminski MS
Leuk Lymphoma; 2015 Feb; 56(2):342-6. PubMed ID: 24730538
[TBL] [Abstract][Full Text] [Related]
6. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
7. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
[TBL] [Abstract][Full Text] [Related]
8. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Hosing C; Munsell M; Yazji S; Andersson B; Couriel D; de Lima M; Donato M; Gajewski J; Giralt S; Körbling M; Martin T; Ueno NT; Champlin RE; Khouri IF
Ann Oncol; 2002 Mar; 13(3):450-9. PubMed ID: 11996478
[TBL] [Abstract][Full Text] [Related]
9. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
10. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD
Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
[TBL] [Abstract][Full Text] [Related]
11. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
[TBL] [Abstract][Full Text] [Related]
13. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
[TBL] [Abstract][Full Text] [Related]
15. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
[TBL] [Abstract][Full Text] [Related]
17. 131I-tositumomab therapy as initial treatment for follicular lymphoma.
Kaminski MS; Tuck M; Estes J; Kolstad A; Ross CW; Zasadny K; Regan D; Kison P; Fisher S; Kroll S; Wahl RL
N Engl J Med; 2005 Feb; 352(5):441-9. PubMed ID: 15689582
[TBL] [Abstract][Full Text] [Related]
18. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
Br J Haematol; 2017 Aug; 178(3):427-433. PubMed ID: 28466487
[TBL] [Abstract][Full Text] [Related]
19. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
Dosik AD; Coleman M; Kostakoglu L; Furman RR; Fiore JM; Muss D; Niesvizky R; Shore T; Schuster MW; Stewart P; Vallabhajosula S; Goldsmith SJ; Leonard JP
Cancer; 2006 Feb; 106(3):616-22. PubMed ID: 16362977
[TBL] [Abstract][Full Text] [Related]
20. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]